UBS Maintains a 'Neutral' on Luminex (LMNX); Strong Consumable Sales Lead To Q1 Beat

UBS maintains a 'Neutral' on Luminex (NASDAQ: LMNX), PT raised from $20 to $21.

UBS analyst says, "Sales and EPS beat Street consensus estimates...Assay development on track; Bulk orders to drive 1H11 consumables sales...For 2011, LMNX forecasts sales of $163-170m (+15-20%), which assumes limited contribution from new assays & normal to light flu season. We project ’11 revs of $170m, w/EPS of $0.33 (was $0.32) as SG&A expense will likely trend higher during the year. For ’12, we see sales of $203m, with EPS of $0.57 (no change)."

For more ratings news on Luminex click here and for the rating history of Luminex click here.

Shares of Luminex closed at $19.85 yesterday.

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• Walmart (WMT) PT Lowered to $130 at UBS as Investment Narrative's Competing Dynamics
• Needham Starts Faeth Therapeutics (FTH) at Buy
• Alibaba (BABA) PT Lowered to $160 at Baird